НАГАБУКУРО Хироси (US),ЭДМОНДСОН Скотт Д. (US),СИНХАРОЙ Мэри Стратерс (US),ДЕННИ Уилльям С. (US),ФРЕНКЛ Тара Л. (US)
申请号：
RU2012118668/13
公开号：
RU2012118668A
申请日:
2010.09.27
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. A method for treating bladder hyperactivity, comprising administering to a patient in need thereof: a β-AR agonist, an antimuscarinic agent and an optional binding selective Mantagonist； wherein the β-AR agonist is selected from the group consisting of: 2. The method according to claim 1, where the antimuscarinic agent has an M / M ratio of less than 40.3. The method of claim 2, wherein the antimuscarinic agent has an M / M ratio of less than 20.4. The method of claim 2, wherein the antimuscarinic agent is selected from the group consisting of: tolterodine, fesoterodine, oxybutynin, solifenacin, propiverine, trospium, imidafenacin and TD6301.5. The method according to claim 4, wherein the antimuscarinic agent is tolterodine or oxybutynin. The method according to claim 1, where the β-AR agonist is selected from the group consisting of: 7. The method of claim 6, wherein the β-AR agonist and antimuscarinic agent are administered to the patient in a weight ratio of 300: 1 to 1: 10.8. The method of claim 6, wherein the antimuscarinic agent is tolterodine, and where the β3-AR agonist and tolterodine are administered to the patient in a weight ratio of 300: 1 to 1: 1.9. The method of claim 1, wherein the method comprises administering to a patient: a β-AR agonist, an antimuscarinic agent, and a selective Mantagonist. The method of claim 9, wherein the antimuscarinic agent has an M / M ratio of greater than 40.11. The method of claim 10, wherein the antimuscarinic agent is darifenacin and the selective Mantagonist is methoctramine. A method for treating bladder hyperactivity, comprising administering to a patient in need thereof: CL316243 ioxybutynin； wherein CL316243 and oxybutynin are administered to the patient in a weight ratio of 1: 1 or 1: 10.13. The method according to claim 1, where the β3-AR agonist, antimuscarinic agent and optional selective Mantagonist are administered simultaneously1. Способ лечения гиперактивности мочевого пузыря, включающий введение пациен
